Barbora Straka

Globally, epilepsy impacts 1%–2%, with one-third resistant to conventional therapies. Research reveals diverse molecular pathways in hyperexcitability, extending beyond ion channels. In vitro human cell culture models promise robust pathogenicity and treatment testing. Model-specific factors should be considered including clinical relevance, feasibility, time requirements, ethics, costs, and benefits. In vitro human cell culture models pave the way for personalized genetic epilepsy therapy.

Methods Patient Identification and Inclusion Criteria Patients who fulfilled the inclusion criterion were identified over the period of 2017–2021. The inclusion criterion was a definite diagnosis of MCD ascertained through neuroimaging or histopathologic examination of the brain tissue. Clinical data were obtained from electronic medical records of Motol University Hospital.